<?xml version="1.0" encoding="UTF-8"?>
<p>An alternative approach to treating secondary bacterial infections, especially AMR pathogens, is the application of phage therapy; using microbial viruses to kill their host, ideally clearing the bacterial infection (
 <xref rid="B3" ref-type="bibr">Altamirano and Barr, 2019</xref>). Bacteriophages are naturally occurring viruses that use bacteria as hosts after employing the host machinery for propagation, including genome replication, protein synthesis, and phage assembly (
 <xref ref-type="fig" rid="F2">Figure 2</xref>). Lysogenic bacteriophages undergo a “dormant” state as non-replicative, genome-integrated phages (
 <xref rid="B64" ref-type="bibr">Monteiro et al., 2019</xref>; 
 <xref rid="B25" ref-type="bibr">Hampton et al., 2020</xref>). Some filamentous phages allow the host to continue to grow and divide while the phages are being produced (
 <xref rid="B51" ref-type="bibr">Loh et al., 2017</xref>, 
 <xref rid="B52" ref-type="bibr">2019</xref>; 
 <xref rid="B45" ref-type="bibr">Kuhn and Leptihn, 2019</xref>). Phage therapy was discovered before antibiotics but the opportunities from the “dawn of the antibiotic era” delayed pursuit of commercial therapeutic phage strategies (
 <xref rid="B73" ref-type="bibr">Pirisi, 2000</xref>; 
 <xref rid="B31" ref-type="bibr">Housby and Mann, 2009</xref>; 
 <xref rid="B60" ref-type="bibr">Manohar et al., 2019c</xref>). With increasing AMR, and depletion of antibiotic resources, phage therapy has once more piqued the interest of the scientific community and pharmaceutical industry (
 <xref rid="B80" ref-type="bibr">Seguin et al., 2006</xref>; 
 <xref rid="B70" ref-type="bibr">Nyangacha et al., 2017</xref>; 
 <xref rid="B60" ref-type="bibr">Manohar et al., 2019c</xref>; 
 <xref rid="B53" ref-type="bibr">Loh and Leptihn, 2020</xref>). Phages and phage-derived therapeutic proteins have advantages and disadvantages as compared with antibiotic therapies (
 <xref ref-type="fig" rid="F3">Figure 3</xref>).
</p>
